eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 158 blog entries.
29 08, 2019

Eiger BioPharmaceuticals to Participate in September Conferences

2019-08-29T20:16:25+00:00

Eiger BioPharmaceuticals to Participate in September Conferences PALO ALTO, Calif. – August 29, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in the following upcoming investor conferences in September: Baird 2019 Global Healthcare Conference at the [...]

Eiger BioPharmaceuticals to Participate in September Conferences2019-08-29T20:16:25+00:00
20 08, 2019

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection

2019-08-20T12:48:11+00:00

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection Fourth Eiger Program Granted Breakthrough Therapy Designation PALO ALTO, Calif., August 20, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and [...]

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection2019-08-20T12:48:11+00:00
6 08, 2019

Eiger BioPharmaceuticals to Participate in Investor Conferences in August

2019-08-06T18:37:29+00:00

Eiger BioPharmaceuticals to Participate in Investor Conferences in August PALO ALTO, Calif. – August 5, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in August. BTIG Biotechnology Conference at St. Regis [...]

Eiger BioPharmaceuticals to Participate in Investor Conferences in August2019-08-06T18:37:29+00:00
17 06, 2019

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)

2019-06-17T20:57:19+00:00

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH) Third Eiger Pipeline Program Granted Breakthrough Therapy Designation PALO ALTO, Calif., June 17, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food [...]

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)2019-06-17T20:57:19+00:00
10 06, 2019

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs

2019-06-10T13:59:43+00:00

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs PALO ALTO, Calif., June 10, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, today announced the appointment of Mark Mannebach, PhD, RPh as Vice President [...]

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs2019-06-10T13:59:43+00:00
5 06, 2019

Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development

2019-06-05T15:04:41+00:00

Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development PALO ALTO, Calif., June 5, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA as Vice President of Global [...]

Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development2019-06-05T15:04:41+00:00
30 05, 2019

Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference

2019-05-30T14:39:10+00:00

Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference PALO ALTO, Calif., May 30, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the Jefferies 2019 Global Healthcare [...]

Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference2019-05-30T14:39:10+00:00
17 05, 2019

Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer

2019-05-17T20:53:43+00:00

Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer PALO ALTO, Calif., May 17, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Apelian will step down as the Company’s Chief Operating Officer and Executive Medical [...]

Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer2019-05-17T20:53:43+00:00
9 05, 2019

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

2019-05-09T20:50:39+00:00

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update First-Ever Phase 3 HDV International “D-LIVR” Study UnderwayNDA and MAA filings for Progeria & Progeroid Laminopathies planned in 2019Strong Balance Sheet with Recent Financing CompletedPALO ALTO, Calif., May 9, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted [...]

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update2019-05-09T20:50:39+00:00
30 04, 2019

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 2019

2019-04-30T13:24:14+00:00

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 2019 PALO ALTO, Calif., April 30, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will participate and present a corporate update at the ChinaBio® Partnering [...]

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 20192019-04-30T13:24:14+00:00
Eiger BioPharmaceuticals © 2018 | All Rights Reserved
Toggle Sliding Bar Area